EGFR and neoplasm: However, in patients with brain metastases and EGFR-mutant tumors, the presence of exon 21 insertion was associated with significantly shorter survival (HR 2.52; 95% CI: 1.22–5.19; p = 0.01) when compared to patients with tumours harbouring exon 19 deletion.